Debra Patt: Exciting Progress in CAR T Therapy Access
Debra Patt, President at Community Oncology Alliance, shared a post on LinkedIn:
“Exciting Progress in CAR T Therapy Access!
Recent FDA updates have introduced new REMS requirements for six groundbreaking CAR T therapies, marking a significant step toward making these innovative treatments more accessible to patients across the country. This change is part of a broader effort to streamline processes, reduce barriers, and bring cutting-edge care closer to the communities that need it most.
In this article featured in Pharmacy Times, Dr. Houston Holmes, who leads the CAR T program at Texas Oncology, discusses the importance of this decision. He emphasizes that these regulatory advancements are crucial in ensuring that patients, no matter where they are, can benefit from these life-changing therapies in their local communities.
This is just one step in a continuous journey to improve access and outcome for patients battling some of the most challenging diseases. We remain committed to supporting innovations that bring hope and healing to patients nationwide.
Read more from Dr. Holmes here.”
More posts featuring Debra Patt on OncoDaily.
Also check out the latest Tabelecleucel (Ebvallo) FDA Update.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023